Embera Management Team
- Robert B. Linke
- Carol A. Gloff, Ph.D.
- Douglas Feltner, M.D.
- Barbara Fox, Ph.D.
- Nicholas Goeders, Ph.D.
- Michael Short
Embera Board of Directors
Scientific Advisory Board
- George Koob, Ph.D.
- Charles O'Brien, MD, Ph.D.
- Bruce McCarthy, MD
- Kathleen Brady, MD, Ph.D.
- Rajita Sinha, Ph.D.
Investors
Bruce McCarthy, MD
Dr. McCarthy is the CEO of Afferent Pharmaceuticals, a clinical development stage company developing treatments for pain, bladder and respiratory disorders based upon P2X3 antagonism. His experience includes over 20 years of neuroscience drug development. At Pfizer, Inc., Dr. McCarthy served as vice president, neuroscience development. Clinicians in his organization obtained approval for Chantix® for smoking cessation. Prior to joining Pfizer, he held various roles at Abbott Laboratories, including venture head, where he managed clinical development programs for neuroscience drug candidates, including ABT-594 (an NNR antagonist for pain) and Depakote. Most recently, as an industry consultant, Dr. McCarthy served as head of development and chief medical officer for several start-up companies including Embera, developing treatments for neurological and psychiatric disorders. Dr. McCarthy received an M.B.A. from Kellogg School of Management, an M.D. from the Johns Hopkins University School of Medicine and a B.S. in biological sciences from Stanford University. He completed his residency in neurology at the University of California, San Francisco.